This is the first study to incorporate Ki-67 expression and built common clinic-pathological factors in the prediction of the survival outcomes after first-line treatment in NSCLC patients with EGFR mutation status and have demonstrated its clinical accuracy, which may help clinical doctors identify potential factors associated with clinical outcomes of first-line therapies or initiate early-intervention treatment regimens for high-risk patient. This evidence concerns the gene MKI67 and non-small cell lung carcinoma.